1-4 of 4
Andrew A. Raubitschek, MD
Close
Sort by
Journal Articles

CD30 as Target for Radioimmunotherapy (RIT) of Lymphoma.

Jan O. Staak, MD, David Colcher, PhD, Satoshi Nagata, PhD, Jianyi Wang, Ira H. Pastan, MD, Andrew A. Raubitschek, MD
Journal: Blood
Blood (2005) 106 (11): 1501.
https://doi.org/10.1182/blood.V106.11.1501.1501
Published: 2005
Journal Articles

The Novel De-Immunized Anti-CD20-IL-2 Immunocytokine DI-Leu16-IL-2 Is Effective in SCID Mice Bearing Rituximab-Resistant Human Lymphoma Xenografts.

Jan O. Staak, MD, David Colcher, PhD, Scott Lauder, Jianyi Wang, Stephen D. Gillies, MD, Andrew A. Raubitschek, MD
Journal: Blood
Blood (2004) 104 (11): 3288.
https://doi.org/10.1182/blood.V104.11.3288.3288
Published: 2004
Journal Articles

Radioimmunotherapy Utilizing the Humanized Anti-CD25 Mab Daclizumab Is Highly Effective in Mice Bearing Human Hodgkin’s Lymphoma Xenografts.

Jan O. Staak, MD, David Colcher, MD, Jianyi Wang, Andreas Engert, MD, Andrew A. Raubitschek, MD
Journal: Blood
Blood (2004) 104 (11): 4632.
https://doi.org/10.1182/blood.V104.11.4632.4632
Published: 2004
Journal Articles

Radiolabeled IL-2-Human Serum Albumin Fusion Protein (Albuleukin™) as a Potential New Reagent for Radioimmunoimaging / Therapy of Hodgkin’s Lymphoma.

Jan O. Staak, MD, David Colcher, PhD, Jianyi Wang, Cynthia Sung, Andrew A. Raubitschek, MD
Journal: Blood
Blood (2004) 104 (11): 4633.
https://doi.org/10.1182/blood.V104.11.4633.4633
Published: 2004